-
Je něco špatně v tomto záznamu ?
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations
F. Millot, M. Ampatzidou, NR. Moulik, S. Tewari, A. Elhaddad, M. Hammad, H. Pichler, T. Lion, A. Tragiannidis, H. Shima, W. An, W. Yang, A. Karow, R. Farah, M. Luesink, M. Dworzak, S. Sembill, B. De Moerloose, P. Sedlacek, KR. Schultz, K. Kalwak,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu konsensus - konference, časopisecké články, přehledy
- MeSH
- chronická fáze myeloidní leukemie * terapie MeSH
- chronická myeloidní leukemie * terapie diagnóza MeSH
- dítě MeSH
- inhibitory proteinkinas * terapeutické užití MeSH
- lidé MeSH
- management nemoci MeSH
- mladiství MeSH
- transplantace hematopoetických kmenových buněk MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- přehledy MeSH
The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs). With the advent of next-generation TKIs and new targeted therapies in the CML field, an international pediatric CML expert panel provides recommendations based on the medical literature (including previous pediatric guidelines), national standards, and treatment principles used in adults with CML-CP. Recommendations include diagnosis of the disease and details on managing the initial steps of care of children and adolescents with newly diagnosed CML-CP, including complications such as leukostasis. The treatment recommendations are based on the initiation of therapy with a first- or second-generation TKI according to the allocated European Treatment and Outcome Study (EUTOS) long-term survival score risk group of the patient. The subsequent steps are based on the results of recommended monitoring which can justify a switch to another TKI or a drug in development if there is resistance or toxicity. The panel also provides recommendations regarding the discontinuation criteria for TKIs in children and adolescents in sustained deep molecular response. Allogeneic HSCT is not recommended as the first-line of treatment for children with CML-CP but is to be considered in case of progression to the advanced phase or failure of several lines of treatment. The present treatment and management recommendations are intended to provide advice to clinicians in view of optimizing the care and the outcome of children and adolescents with CML-CP.
Department of Paediatric Oncology Haematology Royal Marsden NHS Foundation Trust Sutton Sutton UK
Department of Pediatric Hematology and Oncology Medical Faculty Technical University Dresden Germany
Department of Pediatric Hematology Oncology Aghia Sophia Children's Hospital Athens Greece
Department of Pediatric Hematology Oncology and BMT Wroclaw Medical University Wroclaw Poland
Department of Pediatric Oncology Tata Memorial Hospital Homi Bhabha National Institute Mumbai India
Department of Pediatrics Keio University School of Medicine Tokyo Japan
Department of Pediatrics Lebanese American University Medical Center Rizk Hospital Beirut Lebanon
Division of Haematology Oncology Department of Pediatrics McMaster University Hamilton ON Canada
Inserm CIC 1402 University Hospital of Poitiers Poitiers France
Labdia Labordiagnostik Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016256
- 003
- CZ-PrNML
- 005
- 20250731091639.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-025-02543-4 $2 doi
- 035 __
- $a (PubMed)40044960
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Millot, Frédéric $u Inserm CIC 1402, University Hospital of Poitiers, Poitiers, France. f.millot@chu-poitiers.fr $1 https://orcid.org/0000000289124776
- 245 10
- $a Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations / $c F. Millot, M. Ampatzidou, NR. Moulik, S. Tewari, A. Elhaddad, M. Hammad, H. Pichler, T. Lion, A. Tragiannidis, H. Shima, W. An, W. Yang, A. Karow, R. Farah, M. Luesink, M. Dworzak, S. Sembill, B. De Moerloose, P. Sedlacek, KR. Schultz, K. Kalwak, B. Versluys, U. Athale, N. Hijiya, M. Metzler, M. Suttorp
- 520 9_
- $a The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs). With the advent of next-generation TKIs and new targeted therapies in the CML field, an international pediatric CML expert panel provides recommendations based on the medical literature (including previous pediatric guidelines), national standards, and treatment principles used in adults with CML-CP. Recommendations include diagnosis of the disease and details on managing the initial steps of care of children and adolescents with newly diagnosed CML-CP, including complications such as leukostasis. The treatment recommendations are based on the initiation of therapy with a first- or second-generation TKI according to the allocated European Treatment and Outcome Study (EUTOS) long-term survival score risk group of the patient. The subsequent steps are based on the results of recommended monitoring which can justify a switch to another TKI or a drug in development if there is resistance or toxicity. The panel also provides recommendations regarding the discontinuation criteria for TKIs in children and adolescents in sustained deep molecular response. Allogeneic HSCT is not recommended as the first-line of treatment for children with CML-CP but is to be considered in case of progression to the advanced phase or failure of several lines of treatment. The present treatment and management recommendations are intended to provide advice to clinicians in view of optimizing the care and the outcome of children and adolescents with CML-CP.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 12
- $a chronická myeloidní leukemie $x terapie $x diagnóza $7 D015464
- 650 12
- $a chronická fáze myeloidní leukemie $x terapie $7 D015466
- 650 12
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ampatzidou, Mirella $u Department of Pediatric Hematology Oncology (T.A.O.), Aghia Sophia Children's Hospital, Athens, Greece
- 700 1_
- $a Moulik, Nirmalya Roy $u Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India $1 https://orcid.org/0000000156503115
- 700 1_
- $a Tewari, Sanjay $u Department of Paediatric Oncology/Haematology, Royal Marsden NHS Foundation Trust Sutton, Sutton, UK $1 https://orcid.org/0000000214033327
- 700 1_
- $a Elhaddad, Alaa $u Department of Pediatric Oncology, Children's Cancer Hospital, National Cancer Institute, Cairo University, Cairo, Egypt
- 700 1_
- $a Hammad, Mahmoud $u Department of Pediatric Oncology, Children's Cancer Hospital, National Cancer Institute, Cairo University, Cairo, Egypt $1 https://orcid.org/0000000316770360
- 700 1_
- $a Pichler, Herbert $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000151075123
- 700 1_
- $a Lion, Thomas $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u Labdia Labordiagnostik, Vienna, Austria
- 700 1_
- $a Tragiannidis, Athanasios $u 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
- 700 1_
- $a Shima, Haruko $u Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000334328832
- 700 1_
- $a An, Wenbin $u State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, China
- 700 1_
- $a Yang, Wenyu $u State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, China $1 https://orcid.org/0000000248822607
- 700 1_
- $a Karow, Axel $u Division of Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital, Erlangen, Germany
- 700 1_
- $a Farah, Roula $u Department of Pediatrics, Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon $1 https://orcid.org/0000000263921590
- 700 1_
- $a Luesink, Maaike $u Department of Pediatric Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Dworzak, Michael $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- 700 1_
- $a Sembill, Stephanie $u Division of Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital, Erlangen, Germany
- 700 1_
- $a De Moerloose, Barbara $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium $1 https://orcid.org/000000022449539X
- 700 1_
- $a Sedlacek, Petr $u Department of Pediatric Hematology-Oncology, University Hospital Motol, Charles University, Prague, Czech Republic
- 700 1_
- $a Schultz, Kirk R $u Division of Hematology/Oncology/BMT, British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada $1 https://orcid.org/0000000200016438
- 700 1_
- $a Kalwak, Krzysztof $u Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland $1 https://orcid.org/0000000311745799
- 700 1_
- $a Versluys, Birgitta $u Department of Pediatric Blood and Marrow Transplantation, Princess Máxima Center, Utrecht, The Netherlands
- 700 1_
- $a Athale, Uma $u Division of Haematology-Oncology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada
- 700 1_
- $a Hijiya, Nobuko $u Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA $1 https://orcid.org/000000020199054X
- 700 1_
- $a Metzler, Markus $u Division of Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital, Erlangen, Germany $1 https://orcid.org/0000000245231676
- 700 1_
- $a Suttorp, Meinolf $u Department of Pediatric Hematology and Oncology, Medical Faculty, Technical University, Dresden, Germany $1 https://orcid.org/0000000295228838
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 39, č. 4 (2025), s. 779-791
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40044960 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091633 $b ABA008
- 999 __
- $a ok $b bmc $g 2366833 $s 1253381
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 39 $c 4 $d 779-791 $e 20250305 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20250708
